These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 19797880)

  • 1. [Examination of questionnaires regarding diabetic peripheral neuropathy in epalrestat-treated patients and their usefulness in the treatment of the patients during the treatment course].
    Ito A; Ishii-Nozawa R; Ibuki C; Atarashi H; Kataoka H; Takeuchi K
    Yakugaku Zasshi; 2009 Oct; 129(10):1239-47. PubMed ID: 19797880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(ɛ)-carboxymethyl lysine.
    Kawai T; Takei I; Tokui M; Funae O; Miyamoto K; Tabata M; Hirata T; Saruta T; Shimada A; Itoh H
    J Diabetes Complications; 2010; 24(6):424-32. PubMed ID: 19716319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. I-123 MIBG cardiac imaging in diabetic neuropathy before and after epalrestat therapy.
    Utsunomiya K; Narabayashi I; Nakatani Y; Tamura K; Onishi S
    Clin Nucl Med; 1999 Jun; 24(6):418-20. PubMed ID: 10361937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy.
    Nakayama M; Nakamura J; Hamada Y; Chaya S; Mizubayashi R; Yasuda Y; Kamiya H; Koh N; Hotta N
    Diabetes Care; 2001 Jun; 24(6):1093-8. PubMed ID: 11375376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy.
    Ando H; Takamura T; Nagai Y; Kaneko S;
    J Diabetes Complications; 2006; 20(6):367-70. PubMed ID: 17070440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial.
    Hotta N; Akanuma Y; Kawamori R; Matsuoka K; Oka Y; Shichiri M; Toyota T; Nakashima M; Yoshimura I; Sakamoto N; Shigeta Y
    Diabetes Care; 2006 Jul; 29(7):1538-44. PubMed ID: 16801576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis.
    Okamoto H; Nomura M; Nakaya Y; Uehara K; Saito K; Kimura M; Chikamori K; Ito S
    Intern Med; 2003 Aug; 42(8):655-64. PubMed ID: 12924487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy.
    Ramirez MA; Borja NL
    Pharmacotherapy; 2008 May; 28(5):646-55. PubMed ID: 18447661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of 24 weeks of treatment with epalrestat, an aldose reductase inhibitor, on peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus.
    Uchida K; Kigoshi T; Nakano S; Ishii T; Kitazawa M; Morimoto S
    Clin Ther; 1995; 17(3):460-6. PubMed ID: 7585850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac sympathetic neuropathy and effects of aldose reductase inhibitor in streptozotocin-induced diabetic rats.
    Kurata C; Okayama K; Wakabayashi Y; Shouda S; Mikami T; Tawarahara K; Sugiyama T
    J Nucl Med; 1997 Nov; 38(11):1677-80. PubMed ID: 9374332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of the aldose reductase inhibitor on diabetic polyneuropathy--the efficacy of F wave measurement].
    Shimada H; Miki T; Kyogoku I; Kawagishi T; Inaba M; Okuno Y; Nishizawa Y; Morii H
    No To Shinkei; 1998 Sep; 50(9):817-20. PubMed ID: 9789304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy.
    Hotta N; Kawamori R; Fukuda M; Shigeta Y;
    Diabet Med; 2012 Dec; 29(12):1529-33. PubMed ID: 22507139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic Neuropathy Study Group in Japan.
    Hotta N; Sakamoto N; Shigeta Y; Kikkawa R; Goto Y
    J Diabetes Complications; 1996; 10(3):168-72. PubMed ID: 8807467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG.
    Iyer S; Sam FS; DiPrimio N; Preston G; Verheijen J; Murthy K; Parton Z; Tsang H; Lao J; Morava E; Perlstein EO
    Dis Model Mech; 2019 Nov; 12(11):. PubMed ID: 31636082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of aldose reductase inhibitor ONO 2235 on reduced sympathetic nervous system activity and peripheral nerve disorders in STZ-induced diabetic rats.
    Yoshida T; Nishioka H; Yoshioka K; Nakano K; Kondo M; Terashima H
    Diabetes; 1987 Jan; 36(1):6-13. PubMed ID: 3025043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of aldose reductase inhibitor on microneurographically assessed peripheral sympathetic nerve activity in rats.
    Sato D; Kusunoki M; Shinzawa G; Feng Z; Nishina A; Nakamura T
    Auton Neurosci; 2015 Dec; 193():69-73. PubMed ID: 26272532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effect of epalrestat on cardiac autonomic neuropathy in subjects with non-insulin dependent diabetes mellitus.
    Ikeda T; Iwata K; Tanaka Y
    Diabetes Res Clin Pract; 1999 Mar; 43(3):193-8. PubMed ID: 10369429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A placebo-controlled double-blind study of epalrestat (ONO-2235) in patients with diabetic neuropathy.
    Goto Y; Hotta N; Shigeta Y; Sakamoto N; Kito S; Matsuoka K; Takahashi A; Kikkawa R; Sakuma A
    Diabet Med; 1993; 10 Suppl 2():39S-43S. PubMed ID: 8334840
    [No Abstract]   [Full Text] [Related]  

  • 19. The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation.
    He J; Gao HX; Yang N; Zhu XD; Sun RB; Xie Y; Zeng CH; Zhang JW; Wang JK; Ding F; Aa JY; Wang GJ
    Acta Pharmacol Sin; 2019 Jan; 40(1):86-97. PubMed ID: 29930278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of aldose reductase inhibitor on cutaneous nerve fiber length in diabetic patients.
    Yasuda H; Hirai A; Joko M; Terada M; Kawabata T; Maeda K; Haneda M; Kashiwagi A; Maeda T; Kikkawa R
    Diabetes Care; 2000 May; 23(5):705. PubMed ID: 10834436
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.